KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Debt to Equity (2016 - 2025)

Pacira BioSciences has reported Debt to Equity over the past 14 years, most recently at $0.54 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.54 for Q4 2025, down 28.59% from a year ago — trailing twelve months through Dec 2025 was $0.54 (down 28.59% YoY), and the annual figure for FY2025 was $0.54, down 28.59%.
  • Debt to Equity for Q4 2025 was $0.54 at Pacira BioSciences, up from $0.52 in the prior quarter.
  • Over the last five years, Debt to Equity for PCRX hit a ceiling of $0.94 in Q4 2021 and a floor of $0.12 in Q2 2024.
  • Median Debt to Equity over the past 5 years was $0.37 (2025), compared with a mean of $0.37.
  • Biggest five-year swings in Debt to Equity: plummeted 71.84% in 2023 and later surged 428.36% in 2024.
  • Pacira BioSciences' Debt to Equity stood at $0.94 in 2021, then tumbled by 60.87% to $0.37 in 2022, then crashed by 61.26% to $0.14 in 2023, then skyrocketed by 428.36% to $0.75 in 2024, then decreased by 28.59% to $0.54 in 2025.
  • The last three reported values for Debt to Equity were $0.54 (Q4 2025), $0.52 (Q3 2025), and $0.4 (Q2 2025) per Business Quant data.